David R. Parkinson, M.D.
David Parkinson, M.D. has served as a Director on CTI’s Board of Directors since June 2017. Dr. Parkinson is President and Chief Executive Officer of ESSA Pharmaceuticals, Inc. Prior, he was a Venture Partner at New Enterprise Associates, Inc. Dr. Parkinson also served as President and Chief Executive Officer of Nodality, Inc., a biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy; Senior Vice President, Oncology Research and Development at Biogen Idec, where he oversaw all oncology discovery research efforts and the development of the oncology pipeline; and Vice President, Oncology Development at Amgen and Vice President, Global Clinical Oncology Development at Novartis. Dr. Parkinson served as Chief of the Investigational Drug Branch and then as Acting Associate Director of the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute. He is past Chairman of the U.S. Food and Drug Administration’s (FDA) Biologics Advisory Committee and past Member of the FDA Science Board, and he is a recipient of the FDA’s Cody Medal. Dr. Parkinson earned his M.D. from the University of Toronto. He completed his internship, Internal Medicine residency, and Hematology Fellowship at Royal Victoria Hospital at McGill University in Montreal, and a research fellowship at New England Medical Center at Tufts University.